Subscribe
eldora-ellison
28 October 2020BiotechnologySarah Morgan

LSPN Connect: Eldora Ellison on PTAB denials, CRISPR and section 101

Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler  Goldstein & Fox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
LSPN Connect: Monetising your IP portfolio
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Genetics
Webinar: Plenty to fight for in CRISPR IP battle
26 March 2020   Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Big Pharma
LSPN Connect: Monetising your IP portfolio
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Genetics
Webinar: Plenty to fight for in CRISPR IP battle
26 March 2020   Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.

More on this story

Big Pharma
LSPN Connect: Monetising your IP portfolio
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Genetics
Webinar: Plenty to fight for in CRISPR IP battle
26 March 2020   Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler